Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with delta in COVID-19 vaccinated individuals

Thomas Lechmere[1]#, Luke B. Snell[2]#, Carl Graham[1], Jeffrey Seow[1], Zayed A. Shalim[1], Themoula Charalampous,[2] Adela Alcolea-Medina,[2] Rahul Batra,[2] Gaia Nebbia,[2] Jonathan D. Edgeworth[2], Michael H. Malim[1], Katie J. Doores[1] *

[1]Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, UK.

[2]Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, London, UK.

# These authors contributed equally

* To whom correspondence should be addressed: katie.doores@kcl.ac.uk

Abstract:

Numerous studies have shown that a prior SARS-CoV-2 infection can greatly enhance the antibody response to COVID-19 vaccination, with this so called "hybrid immunity" leading to greater neutralization breadth against SARS-CoV-2 variants of concern. However, little is known about how breakthrough infection (BTI) in COVID-19 vaccinated individuals will impact the magnitude and breadth of the neutralizing antibody response. Here, we compared neutralizing antibody responses between unvaccinated and COVID-19 double vaccinated individuals (including both AZD1222 and BNT162b2 vaccinees) who have been infected with the delta (B.1.617.2) variant. Rapid production of Spike-reactive IgG was observed in the vaccinated group providing evidence of effective vaccine priming. Overall, potent cross-neutralizing activity against current SARS-CoV-2 variants of concern was observed in the BTI group compared to the infection group, including neutralization of the omicron (B.1.1.529)

variant. This study provides important insights into population immunity where transmission levels remain high and in the context of new or emerging variants of concern.

Introduction:

COVID-19 vaccines have proven to be critical in controlling SARS-CoV-2 infections worldwide. Vaccines based on the SARS-CoV-2 Wuhan-1 Spike protein generate neutralizing antibodies which constitute an important component of the protective capacity of COVID-19 vaccines. Since the beginning of the global pandemic, variants of SARS-CoV-2 have arisen which encode mutations in the Spike protein. Until November 2021, the dominant circulating variant was B.1.617.2 (delta), but B.1.1.529 (omicron) is rapidly increasing globally (https://www.nicd.ac.za/wpcontent/uploads/2021/11/Update-of-SA-sequencing-data-from-GISAID-26-Nov_Final.pdf). There is concern that SARS-CoV-2 variants of concern (VOCs) might lead to a reduction in vaccine efficacy, in particular against omicron which encodes 31 amino acid changes in the Spike protein.

To generate high titres of Spike reactive IgG with potent neutralization, double vaccination is required for both the BNT162b2 (based on mRNA encoding a stabilized Spike) and AZD1222 (based on a chimp adenovirus encoded Spike) vaccines (Ramasamy et al., 2021; Walsh et al., 2020). Importantly, several studies have shown that SARS-CoV-2 infection prior to vaccination can boost antibody titres and neutralizing activity, with this so called “hybrid immunity” leading to greater neutralization breadth against SARS-CoV-2 VOCs (Goel et al., 2021; Manisty et al., 2021; Reynolds et al., 2021; Saadat et al., 2021; Stamatatos et al., 2021). However, little is known about how breakthrough infection (BTI) in COVID-19 double vaccinated individuals will impact the magnitude and breadth of the neutralizing antibody response (Collier et al., 2021; Hacisuleyman et al., 2021; Kitchin, 2021), particularly in the face of the omicron variant where preliminary data shows that a 3rd vaccine dose is required for robust neutralization activity (Cameroni, 2021; Doria-Rose, 2021; Garcia-Beltran, 2021; Gruell, 2021; Schmidt, 2021) and predicted for high vaccine efficacy (Khoury, 2021). This information would provide important insights into population immunity in areas where

transmission levels remain high and where omicron is rapidly becoming the dominant strain. Here, we compared the magnitude and breadth of the antibody response in individuals infected with the SARS-CoV-2 delta VOC (vaccine naïve) to the antibody response in individuals who were double vaccinated prior to delta infection (breakthrough infection, BTI).

Results

Cohort description

We identified 42 individuals admitted to St Thomas' hospital who had previously received two COVID-19 vaccinations and subsequently tested positive for COVID-19. We note that at the time of writing, from the patients admitted to St Thomas' Hospital with COVID-19 since the emergence of delta (n=635), 260 cases out of 332 (78%) where vaccination was known were either unvaccinated or partially vaccinated (one inoculation). In this study, 30/42 (71%) of patients in the BTI group were admitted to hospital due to COVID-19, of which 11/30 (37%) patients experienced severe disease (severity 4-5). 29/30 (97%) patients had underlying health conditions that predispose to severe disease and aged between 20-103 years (median age 77 years, IQR 59-86) (**Table S1**). The remaining 12 participants in the BTI group (29%) were asymptomatic and admitted for reasons other than COVID-19. Patients were aged between 24-96 years (median age 62 years, IQR 37-72). Overall, the BTI group included individuals receiving both the AZD1222 vaccine (n = 23) and the BNT162b2 vaccine (n = 19). Discarded serum samples were collected between 0-53 days post onset of symptoms (POS) and longitudinal serum samples were collected where possible. The number of days post second vaccine ranged from 29-179 days (median 109 days).

Sera (n = 19) were also collected from unvaccinated individuals admitted to St Thomas' hospital due to COVID-19 who had a confirmed infection with the SARS-CoV-2 delta variant and experienced a range of disease severities with 9/19 (47%) patients experiencing severe disease (severity 4-5). Patients were aged between 25-82 years (median age 39 years, IQR 30-51) and 9/19 (47%) had underlying health conditions (**Table S2**). Sera were collected between 12-22 days POS.

84

85 **IgG and IgM to Spike in breakthrough infection**

86 First, we measured the IgG and IgM responses to recombinant Spike (both WT and
87 delta) in the two groups by ELISA. Sera from unvaccinated individuals infected with the delta
88 variant at 12-22 days POS had higher delta Spike IgM levels than delta Spike IgG (**Figure 1A**)
89 indicative of a primary immune response. Slightly higher IgG and IgM titres were observed
90 against the delta recombinant Spike compared to WT Spike (**Figure 1B**).

91 For sera collected 12-22 days POS in the BTI group, delta Spike IgM levels in the BTI
92 group were lower than the delta Spike IgG level (**Figure 1C**) indicative of a recall response. A
93 similar trend was observed for both AZD1222 and BNT162b2 vaccinated individuals (**Figure**
94 **S1A**). Where sequential serum samples were collected, nine individuals had undetectable or
95 a very low Spike IgG response at the earliest timepoint POS (**Figure 1D and Figure S1B**).
96 However, high titres of Spike specific IgG were detected several days later with only modest
97 increases in IgM titres (**Figure 1E-F**). Six donors had IgG against Spike at early time points
98 but lacked IgG to the SARS-CoV-2 Nucleoprotein (**Figure S1C-D**). Although this may provide
99 insight into Spike IgG levels prior to infection, it is more likely due to a rapid Spike IgG recall
100 response compared to a de novo IgG response to Nucleoprotein (**Figure 1E-F)**. One
101 participant (a renal transplant patient) had a high IgM response and low IgG response, similar
102 to the vaccine naïve group, which suggests failed vaccine priming (**Figure 1C**). Interestingly,
103 unlike the vaccine naïve group, the IgG and IgM titres against the WT and delta Spikes were
104 comparable in the BTI group (**Figures 1D**).

105 Overall, these results indicate a rapid recall response due to prior vaccination in the
106 BTI group and a primary immune response in the vaccine naïve group.

107

108 **Neutralization activity following breakthrough infection**

109 Next, we measured neutralization breadth and potency in the two groups using HIV-1
110 (human immunodeficiency virus type-1) based virus particles, pseudotyped with SARS-CoV-
111 2 Spike from different VOCs (wild-type (Wuhan), alpha (B.1.1.7), delta (B.1.617.2), mu

112 (B.1.621) and beta (B.1.351)) and a HeLa cell-line stably expressing the ACE2 receptor (Seow
113 et al., 2020). The majority (17/19, 89%) of the vaccine naïve group produced a robust
114 homologous neutralizing response against the delta VOC (**Figure 2A**). Cross-neutralization
115 of the parental strain and other VOCs was detected for most individuals, albeit at a reduced
116 potency. As we have reported previously (Dupont et al., 2021), the greatest reduction was
117 observed against beta with a 9.4-fold reduction in the GMT, reflecting greater antigenic
118 distance.

119 Sera collected between 12-22 days POS from individuals in the BTI group showed a
120 robust homologous neutralizing response as well as strong cross-neutralization of the parental
121 variant and VOCs (**Figure 2B**). Only a 1.2-fold reduction in GMT was observed against the
122 more neutralization resistant beta VOC. Several individuals in the BTI group with sera
123 collected soon after onset of symptoms showed no or very low neutralization against both WT
124 and delta variants, however, potent neutralizing activity was detected several days later
125 (**Figure 2C&D and S2A**). Geometric mean titres against the five variants were very similar
126 between AZD1222 and BNT162b2 vaccinated individuals (**Figure S2B**). Three participants in
127 the BTI group either failed to produce neutralizing antibodies or had titres close to baseline
128 despite vaccination and SARS-CoV-2 infection. These individuals had underlying health
129 conditions including cancer (one participant was undergoing rituximab treatment) and type-2
130 diabetes.

131 As would have been anticipated, IgG ED_{50} values correlated best with ID_{50} values for
132 the BTI group whereas IgM ED_{50} values correlated best with ID_{50} values for the unvaccinated
133 group (**Figure 2E&F**) further highlighting the priming capacity of both the AZ and BNT162b2
134 vaccines.

135

136 **BTI generates neutralizing activity against omicron**

137 In November 2021, omicron (B.1.1.529) was identified that encoded 31 amino acid
138 mutations in the Spike protein (**Figure 3A**). Initial studies suggest that these mutations lead
139 to large reductions in neutralization of sera from double vaccinated individuals. However,

140 administration of a third vaccine dose greatly enhances neutralization titres against omicron
141 suggesting incomplete neutralization escape (Cameroni, 2021; Cele et al., 2021; Doria-Rose,
142 2021; Garcia-Beltran, 2021; Gruell, 2021; Schmidt, 2021). Neutralization activity of a subset
143 of 14 sera from the vaccine naïve group and 15 sera from the BTI group were measured
144 against WT, delta and omicron variants (**Figure 3B&D**). In delta infected individuals, a 28.9-
145 fold reduction in GMT against omicron compared to delta was measured compared to a 6.9-
146 fold reduction in GMT for WT. Sera from two participants did not neutralize the omicron variant
147 at the lowest dilution point (1:25). In contrast, all 15 sera from the BTI group neutralized the
148 omicron variant with only a 4.5-fold reduction in GMT against omicron compared to delta GMT
149 (**Figure 3C&E**). Three individuals showed a 21- to 81-fold reduction in ID_{50} against omicron
150 compared to ID_{50} against delta, all of which were receiving treatment for underlying health
151 conditions. These results further highlight the breadth of the neutralizing antibody response
152 following BTI with the delta variant.
153
154 **Discussion**
155 These data demonstrate that whilst 2-doses of COVID-19 vaccine (both BNT162b2 or
156 AZD1222) was not sufficient to provide sterilizing immunity against SARS-CoV-2 infection in
157 these particular individuals, breakthrough infection generated a strong anamnestic response.
158 Although this study cannot provide information on the titre of neutralizing antibody required for
159 protection against infection with the delta VOC, longitudinal sampling revealed that six
160 participants who had undetectable neutralization or ID_{50} ~25 against delta VOC at the earliest
161 timepoint sampled rapidly developed IgG to Spike and serum neutralizing activity upon
162 infection showing both AZD1222 and BNT162b2 vaccination primed their immune system to
163 respond rapidly upon SARS-CoV-2 infection. 30/42 (71%) of the BTI group were admitted to
164 hospital due to COVID-19 after BTI, the median age was 77 years and only 1/30 (3%) had no
165 comorbidities that would predispose to severe disease. This suggests the group admitted with
166 BTI were at particular risk of severe disease due to advancing age and/or co-morbidities.
167 Indeed, advancing age was the main criterion with which vaccination schedule was based in

168 the UK, meaning that those over 70 years were amongst the first to be offered vaccination in
169 January 2021. As such, vaccine-induced immunity may have waned in this group due to the
170 longer interval between vaccination and exposure, facilitating subsequent BTI (Levin et al.,
171 2021; Mizrahi et al., 2021; Shrotri et al., 2021; Tartof et al., 2021). Indeed, the median time
172 elapsed since last vaccination in the BTI group was 109 days with 24/30 (80%) being
173 vaccinated over 10 weeks prior to symptom onset. Others have described waning of vaccine-
174 induced immunity against delta after 10 weeks, especially in older age groups (Andrews, 2021;
175 Israel et al., 2021). Notably, the unvaccinated group were much younger and a large
176 proportion had no co-morbidities.

177 When comparing the immune response of the BTI group and the vaccine naïve group,
178 we observe that prior vaccination led to a more potent and broader neutralizing antibody
179 response during the acute phase of infection, including against the highly mutated omicron
180 variant. As we do not have matched sera collected prior to breakthrough infection we cannot
181 comment on the breadth of the nAb response prior to infection. However, in this vaccinated
182 cohort, boosting is occurring with a heterologous Spike which may contribute to the
183 broadening of the serum neutralizing activity. In addition, all individuals in this study received
184 an extended booster regime (8-12 weeks post prime) which has been suggested to generate
185 a broader response than the short (3-4 week) boost regime (Payne et al., 2021; Tauzin, 2021).
186 Further studies examining the antibody response at the monoclonal level is needed to
187 determine if the broader serum activity is due to individual antibodies or a de novo response
188 directed against the delta Spike. Broadening of the neutralizing antibody response has been
189 reported at later timepoints following natural infection (~6-10 months) (Dupont et al., 2021;
190 Gaebler et al., 2021) and therefore, despite narrow serum neutralization breadth in the vaccine
191 naïve group, convalescent sera collected at later timepoints would be expected to have
192 broader neutralizing activity. The large decrease in neutralization of viral particles
193 pseudotyped with omicron Spike by sera from delta infected individuals highlights the large
194 antigenic distance between the delta and omicron Spike glycoproteins (Dupont et al., 2021;
195 Liu et al., 2021).

196 Although the omicron VOC is more neutralization resistant, several studies have
197 reported smaller fold-reductions in serum neutralization potency for omicron following 3-doses
198 of COVID-19 vaccination (range 4 - 7 fold) compared to those who had received only 2 vaccine
199 doses (range 20-fold to >40-fold) (Cameroni, 2021; Doria-Rose, 2021; Garcia-Beltran, 2021;
200 Gruell, 2021; Liu, 2021; Schmidt, 2021). Overall, the data presented here suggest that a
201 breakthrough SARS-CoV-2 delta infection is also acting as an effective booster which could
202 provide broad protection against current VOCs, including omicron. As new VOCs arise with
203 new/unique combinations of mutations, our data suggests a broad neutralizing antibody
204 response generated by a combination of vaccination and infection may provide immunity
205 against other/emerging VOCs. This study provides important insights into population immunity
206 and can inform public health measures where SARS-CoV-2 transmission levels remain high.
207
208

209 **Methods**

210 **Ethics**

211 Collection of surplus serum samples was approved by South Central – Hampshire B
212 REC (20/SC/0310). SARS-CoV-2 cases were diagnosed by RT–PCR of respiratory samples
213 at St Thomas' Hospital, London. Sera were selected on the availability of longitudinal samples
214 and knowledge of timing and type of COVID-19 vaccination.

215

216 **COVID-19 severity classification.**

217 Disease severity was determined as previously described (Dupont et al., 2021; Seow et al.,
218 2020). Patients diagnosed with COVID-19 were classified as follows: (0) Asymptomatic or no
219 requirement for supplemental oxygen; (1) Requirement for supplemental oxygen (fraction of
220 inspired oxygen (*F*iO2) < 0.4) for at least 12 h; (2) Requirement for supplemental oxygen (*F*iO2
221 ≥ 0.4) for at least 12 h; (3) Requirement for non-invasive ventilation/continuous positive airway
222 not a candidate for escalation above level one (ward-based) care; (4) Requirement for
223 intubation and mechanical ventilation or supplemental oxygen (*F*iO2 > 0.8) and peripheral
224 oxygen saturations <90% (with no history of type 2 respiratory failure (T2RF)) or <85% (with
225 known T2RF) for at least 12 h; (5) Requirement for ECMO.

226

227 **Virus sequencing**

228 Delta variant infection was confirmed using whole genome sequencing as previously
229 described (Dupont et al., 2021) or using MT-PCR (Hale et al., 2021).

230

231 **Plasmids.**

232 WT, B.1.1.7, B.1.351, B.1.621, B.1.617.2 and B.1.1.529 codon optimized Spike
233 plasmids were obtained from Wendy Barclay (Imperial College London). The final 19 amino
234 acids were removed using an K1255* mutation. B.1.1.7 mutations introduced were ΔH69/V70,
235 ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H. B.1.351 mutations

236 introduced were D80A, D215G, Delta242-244, R246I, K417N, E484K, N501Y, D614G,
237 A701V. B.1.617.2 mutations introduced were: T19R, G142D, ∆156-157, R158G, L452R,
238 T478R, D614G, P681R, D950N. B.1.621 mutations introduced were: T95I,
239 Y144T/144insS/Y145N, R346K, E484K, N501Y, D614G, P681H, D950N. B.1.1.529 mutations
240 introduced were: A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D,
241 S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S,
242 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K,
243 Q954H, N969K, L981F.
244
245 **Glycoprotein expression and purification.**
246 The recombinant wild-type (Wuhan-1 strain) and delta (B.1.617.2) consist of a pre-
247 fusion S ectodomain residues 1–1138 with proline substitutions at amino acid positions 986
248 and 987, a GGGG substitution at the furin cleavage site (amino acids 682–685) and an N
249 terminal T4 trimerisation domain followed by a Strep-tag II (Brouwer et al., 2020). Spike was
250 expressed in HEK 293 Freestyle cells and purified using StrepTactinXT Superflow high
251 capacity 50% suspension according to the manufacturer's protocol by gravity flow (IBA Life
252 Sciences).
253 N protein was obtained from the James lab at LMB, Cambridge. The N protein is a
254 truncated construct of the SARS-CoV-2 N protein comprising residues 48–365 with an N
255 terminal uncleavable hexahistidine tag. N was expressed in *E. Coli* using autoinducing media
256 for 7h at 37℃ and purified using immobilised metal affinity chromatography (IMAC), size
257 exclusion and heparin chromatography.
258
259 **Spike IgG titres by ELISA**
260 ELISA was carried out as previously described (Seow et al., 2020). All sera were heat-
261 inactivated at 56°C for 30 mins before use in the in-house ELISA. High-binding ELISA plates
262 (Corning, 3690) were coated with antigen (N or Spike (WT or delta)) at 3 µg/mL (25 µL per
263 well) in PBS overnight at 4°C. Wells were washed with PBS-T (PBS with 0.05% Tween-20)

264 and then blocked with 100 µL 5% milk in PBS-T for 1 hr at room temperature. Wells were
265 emptied and a titration of serum starting at 1:50 and using a 6-fold dilution series in milk was
266 added and incubated for 2 hr at room temperature. Control reagents included CR3009 (2
267 µg/mL), CR3022 (0.2 µg/mL), negative control plasma (1:25 dilution), positive control plasma
268 (1:50) and blank wells. Wells were washed with PBS-T. Secondary antibody was added and
269 incubated for 1 hr at room temperature. IgM was detected using Goat-anti-human-IgM-HRP
270 (horseradish peroxidase) (1:1,000) (Sigma: A6907) and IgG was detected using Goat-anti-
271 human-Fc-AP (alkaline phosphatase) (1:1,000) (Jackson: 109-055-098). Wells were washed
272 with PBS-T and either AP substrate (Sigma) was added and read at 405 nm (AP) or 1-step
273 TMB (3,3′,5,5′-Tetramethylbenzidine) substrate (Thermo Scientific) was added and quenched
274 with 0.5 M H_2S0_4 before reading at 450 nm (HRP). Half-maximal binding (EC_{50}) was calculated
275 using GraphPad Prism. Measurements were carried out in duplicate.
276
277 **SARS-CoV-2 pseudotyped virus particle preparation.**
278 Pseudotyped HIV-1 virus incorporating the SARS-CoV-2 Spike protein (either wild-
279 type, B.1.1.7, B.1.351, B.1 621, B.1.617.2 or B.1.1.529) were prepared as previously
280 described (Dupont et al., 2021). Viral particles were produced in a 10 cm dish seeded the day
281 prior with $5x10^6$ HEK293T/17 cells in 10 ml of complete Dulbecco's Modified Eagle's Medium
282 (DMEM-C, 10% FBS and 1% Pen/Strep) containing 10% (vol/vol) foetal bovine serum (FBS),
283 100 IU/ml penicillin and 100 μg/ml streptomycin. Cells were transfected using 90 μg of PEI-
284 Max (1 mg/mL, Polysciences) with: 15μg of HIV-luciferase plasmid, 10 μg of HIV 8.91 gag/pol
285 plasmid and 5 μg of SARS-CoV-2 spike protein plasmid.(Grehan et al., 2015; Thompson et
286 al., 2020) The supernatant was harvested 72 hours post-transfection. Pseudotyped virus
287 particles was filtered through a 0.45μm filter, and stored at -80°C until required.
288
289 **Neutralization assay with SARS-CoV-2 pseudotyped virus.**

290 Serial dilutions of serum samples (heat inactivated at 56°C for 30mins) were prepared
291 with DMEM media (25µL) (10% FBS and 1% Pen/Strep) and incubated with pseudotyped
292 virus (25µL) for 1-hour at 37°C in half-area 96-well plates. Next, Hela cells stably expressing
293 the ACE2 receptor were added (10,000 cells/25µL per well) and the plates were left for 72
294 hours. Infection levels were assessed in lysed cells with the Bright-Glo luciferase kit
295 (Promega), using a Victor™ X3 multilabel reader (Perkin Elmer). Each serum sample was run
296 in duplicate and was measured against the five SARS-CoV-2 variants within the same
297 experiment using the same dilution series.
298
299 **Statistical analysis.**
300 Analyses were performed using GraphPad Prism v.8.3.1.
301
302

303 **Figures**

304



305

306

307 **Figure 1: Differences in antibody binding between delta infected individuals and**

308 **COVID-19 vaccinated individuals experiencing delta breakthrough infection. A)**

309 Difference in IgG and IgM titres for sera collected 12-22 days POS for the delta infection

310 (vaccine naïve) group. **B)** Comparison of the IgG and IgM ED_{50} values against recombinant

311 WT and delta Spikes for the vaccine naïve group. Black horizontal lines show the geometric

312 mean titres. **C)** Difference in IgG and IgM titres for sera for the BTI group. **D)** Comparison of

313 the IgG and IgM ED_{50} values against recombinant WT and delta Spikes for the BTI group.
314 Black horizontal lines show the geometric mean titres. **E)** Longitudinal IgG ED_{50} against
315 recombinant delta Spike in the BTI group. **F)** Longitudinal IgM ED_{50} against recombinant delta
316 Spike in the BTI group. Donors with IgM>IgG are shown in blue, donors who do not
317 seroconvert are shown in red, donors with high Spike IgG but no N IgG at <7days POS are
318 shown in orange, and donors with low Spike IgG at <7 days POS that rapidly increases are
319 shown in yellow.



Figure 2: Differences in neutralizing antibody response between delta infected individuals and COVID-19 vaccinated individuals experiencing delta breakthrough infection. ID_{50} of neutralization against WT (black) and VOCs alpha (blue), delta (purple), mu (red) and beta (orange) for sera from **A)** SARS-CoV-2 delta infected individuals and **B)** BTI individuals. Black line shows the geometric mean titre. Fold decrease in GMT compared to delta are shown above. Longitudinal neutralization potency of sera in BTI individuals against

327 **C)** WT pseudovirus particles and **D)** delta pseudovirus particles. Donors with IgM>IgG are
328 shown in blue, donors who do not seroconvert are shown in red, donors with high Spike IgG
329 but no N IgG at <7days POS are shown in orange, and donors with low Spike IgG at <7 days
330 POS that rapidly increases are shown in yellow. Data for the alpha, beta and mu VOCs is
331 shown in **Figure S2A**. Correlation (Spearman, r) between ID_{50} of neutralization and IgM or
332 IgG ED_{50} for delta Spike binding for **E)** delta infected individuals (IgM: $r = 0.92$, $r^2 = 0.90$, p
333 <0.0001 and IgG: $r = 0.66$, $r^2 = 0.43$, $p = 0.001$) and **F)** COVID-19 vaccinated individuals
334 experiencing breakthrough infection (IgM: $r = 0.61$, $r^2 = 0.38$, $p <0.0001$ and IgG: $r = 0.83$, r^2
335 $= 0.75$, $p <0.0001$). A linear regression was used to calculate the goodness of fit (r^2). The
336 dotted lines represent the lowest serum dilution used in each assay. IgG is shown with yellow
337 circles and IgM shown with red circles.


A
B1.617.2
(Delta)
Δ156-157
T478R
T19R
G142D
R158G
L452R
D614G
P681R
D950N
B.1.1.529
(Omicron)
Δ69-70
Δ143-145
ins214EPE
S371L
S375F
G446S
T478K
Q493K
Q498R
Y505H
T547K
D614G
N679K
N969K
A67V
T95I
G142D
Δ211/L212I
G339D
S373P
K417N
N440K
S477N
E484A
G496S
N501Y
H655Y
P681H
N764K
D796Y
N856K
Q954H
L981F
B
C
x6.9
x28.9
x2.5
x4.5
ID50 (Log)
100000
10000
1000
100
10
WT
B.1.617.2
B.1.1.529

338

339 **Figure 3: Neutralization of omicron in BTI and delta infected individuals. A)** Schematic
340 showing mutations in the delta (B.1.617.2) and omicron (B.1.1.529) Spikes. Select sera from
341 **B)** SARS-CoV-2 delta infected (vaccine naïve) individuals (13-22 days POS) and **C)** BTI
342 individuals (12-21 days POS) was tested against WT, delta and omicron VOCs. ID_{50} of
343 neutralization against WT (black) and VOCs delta (purple), and omicron (turquoise) for each
344 participant are linked. Geometric mean titres against WT, delta and omicron VOCs for **D)**
345 SARS-CoV-2 delta infected individuals (13-22 days POS) and **E)** BTI individuals (12-21 days
346 POS). Black line shows the geometric mean titre. Fold decrease in GMT against omicron
347 compared to WT and delta are shown above.

Acknowledgements

This work was funded by; Fondation Dormeur, Vaduz for funding equipment to KJD, Huo Family Foundation Award to MHM, KJD, MRC Genotype-to-Phenotype UK National Virology Consortium (MR/W005611/1 to MHM, KJD), and Wellcome Trust Investigator Award 106223/Z/14/Z to MHM. CG is supported by the MRC-KCL Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). This work was supported by the Department of Health via a National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. This study is part of the EDCTP2 programme supported by the European Union (grant number RIA2020EF-3008 COVAB). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP. This project is supported by a joint initiative between the Botnar Research Centre for Child Health and the European & Developing Countries Clinical Trials Partnership (KJD).

Thank you to Philip Brouwer, Marit van Gils and Rogier Sanders for the Spike protein construct, Leo James and Jakub Luptak for the N protein, Wendy Barclay and Thomas Peacock (Imperial) for providing the Spike plasmids and James Voss and Deli Huang (Scripps) for providing the Hela-ACE2 cells.

References

Andrews, N. (2021). Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. medRxiv.

Brouwer, P.J.M., Caniels, T.G., van der Straten, K., Snitselaar, J.L., Aldon, Y., Bangaru, S., Torres, J.L., Okba, N.M.A., Claireaux, M., Kerster, G.*, et al.* (2020). Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science *369*, 643-650.

Cameroni, E. (2021). Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv.

Cele, S., Jackson, L., Khan, K., Khoury, D.S., Moyo-Gwete, T., Tegally, H., Scheepers, C., Amoako, D., Karim, F., Bernstein, M.*, et al.* (2021). SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv.

Collier, A.Y., Brown, C.M., McMahan, K., Yu, J., Liu, J., Jacob-Dolan, C., Chandrashekar, A., Tierney, D., Ansel, J.L., Rowe, M.*, et al.* (2021). Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts. medRxiv.

Doria-Rose, N.A. (2021). Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies. medRxiv.

Dupont, L., Snell, L.B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T.J.A., Hallett, S.R., Pickering, S., Charalampous, T.*, et al.* (2021). Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat Microbiol *6*, 1433-1442.

Gaebler, C., Wang, Z., Lorenzi, J.C.C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T.Y.*, et al.* (2021). Evolution of antibody immunity to SARS-CoV-2. Nature *591*, 639-644.

Garcia-Beltran, W.F. (2021). mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARSCoV-2 Omicron variant. medRxiv.

Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S., Hicks, P., Meng, W., Rosenfeld, A.M.*, et al.* (2021). Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci Immunol *6*.

Grehan, K., Ferrara, F., and Temperton, N. (2015). An optimised method for the production of MERS-CoV spike expressing viral pseudotypes. MethodsX *2*, 379-384.

Gruell, H. (2021). mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. medRxiv.

Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N.E., Bergh, M., Conlon, E.G., Schaefer-Babajew, D.J., DaSilva, J., Muecksch, F., Gaebler, C.*, et al.* (2021). Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med *384*, 2212-2218.

Hale, R., Crowley, P., Dervisevic, S., Coupland, L., Cliff, P.R., Ebie, S., Snell, L.B., Paul, J., Williams, C., Randell, P.*, et al.* (2021). Development of a Multiplex Tandem PCR (MT-PCR) Assay for the Detection of Emerging SARS-CoV-2 Variants. Viruses *13*.

Israel, A., Merzon, E., Schaffer, A.A., Shenhar, Y., Green, I., Golan-Cohen, A., Ruppin, E., Magen, E., and Vinker, S. (2021). Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. BMJ *375*, e067873.

Khoury, D.S. (2021). A meta-analysis of Early Results to predict Vaccine efficacy against Omicron. medRxiv.

Kitchin, D. (2021).
Ad26.COV2.S breakthrough infections induce high titers of antibodies capable of neutralizing variants of concern. medRxiv.

Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A.*, et al.* (2021). Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med.

Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A.J., Zhao, Y.*, et al.* (2021). Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell.

Liu, L. (2021). Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. bioRxiv.

Manisty, C., Otter, A.D., Treibel, T.A., McKnight, A., Altmann, D.M., Brooks, T., Noursadeghi, M., Boyton, R.J., Semper, A., and Moon, J.C. (2021). Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet *397*, 1057-1058.

Mizrahi, B., Lotan, R., Kalkstein, N., Peretz, A., Perez, G., Ben-Tov, A., Chodick, G., Gazit, S., and Patalon, T. (2021). Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun *12*, 6379.

Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S.C.*, et al.* (2021). Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell *184*, 5699-5714 e5611.

Ramasamy, M.N., Minassian, A.M., Ewer, K.J., Flaxman, A.L., Folegatti, P.M., Owens, D.R., Voysey, M., Aley, P.K., Angus, B., Babbage, G.*, et al.* (2021). Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet *396*, 1979-1993.

Reynolds, C.J., Pade, C., Gibbons, J.M., Butler, D.K., Otter, A.D., Menacho, K., Fontana, M., Smit, A., Sackville-West, J.E., Cutino-Moguel, T.*, et al.* (2021). Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science.

Saadat, S., Rikhtegaran Tehrani, Z., Logue, J., Newman, M., Frieman, M.B., Harris, A.D., and Sajadi, M.M. (2021). Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA *325*, 1467-1469.

Schmidt, F. (2021). Plasma neutralization properties of the SARS-CoV-2 Omicron variant. medRxiv.

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K.J.A., Hemmings, O., O'Byrne, A., Kouphou, N., Galao, R.P.*, et al.* (2020). Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol *5*, 1598-1607.

Shrotri, M., Navaratnam, A.M.D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W.L.E., Patel, P., Kovar, J.*, et al.* (2021). Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet *398*, 385-387.

Stamatatos, L., Czartoski, J., Wan, Y.H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M.F., MacCamy, A.J.*, et al.* (2021). mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science.

Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N., Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S.*, et al.* (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet *398*, 1407-1416.

Tauzin, A. (2021). Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. medRxiv.

Thompson, C.P., Grayson, N.E., Paton, R.S., Bolton, J.S., Lourenco, J., Penman, B.S., Lee, L.N., Odon, V., Mongkolsapaya, J., Chinnakannan, S.*, et al.* (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill *25*.

Walsh, E.E., Frenck, R.W., Jr., Falsey, A.R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M.J., Bailey, R.*, et al.* (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med *383*, 2439-2450.